الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 85 |  |  |
| | | from | 85 | | |
Abstract
Sinonasal cancer (SNC) is a rare disease, with an incidence of less than 1 case per 100,000 annually, representing 3% of all head and neck cancers. Almost half of the tumors originate in the nasal cavity. The majority of other tumors originate in the maxillary or ethmoid sinuses, while tumors of the frontal and sphenoid sinuses are rare.
The current study is a retrospective analysis for the hospital records to shortlist all patients who were treated for sinonasal epithelial malignant tumors at Menoufia university hospitals. Collected patients data were from the oncology department and otorhinolaryngology department records from 2014 to 2019. Patients of the study were selected according to inclusion and exclusion criteria. In our retrospective study, the overall mean patient age was 52.93 years (range 26–82 years) with a male to female ratio of 1.56:1.
The main presentation of our studied cases with complete response is nasal obstruction (75%). While 35% of patients with complete response had headache followed by epistaxis (30%), otalgia (20%), hearing impairment (15%) and facial pain (10%). While 53.3% of patients with partial response had either headache or hearing impairment followed by epistaxis (46.7%), otalgia (40%), nasal obstruction (6.7%%), tinnitus (6.7%%) and facial pain (6.7%).
Suspicion of the rhino-otologist should be higher with manifestation like headache, unilateral secretory otitis media and unilateral epistaxis or nasal obstruction especially in old-aged patients. Neoadjuvant chemoradiotherapy is one of the best modalities of treatment of sinonasal malignancies especially with better response and fate of the patient.